Laura Testa
Impact in
- Cancer Research top 2%
- Breast Cancer Treatment Studies
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer survivorship and care
Papers in
-
- Breast Cancer Treatment Studies 25
- Oncology 27
- Cancer Immunotherapy and Biomarkers 10
- Cancer Treatment and Pharmacology 4
- HER2/EGFR in Cancer Research 4
- Co-authors
- Nadia Harbeck (8 shared papers)Seock‐Ah Im (7 shared papers)Rebecca Alexandra Dent (3 shared papers)Eric P. Winer (5 shared papers)Vassiliki Karantza (5 shared papers)Peter E. Schmid (6 shared papers)Stefania Zambelli (3 shared papers)Javier Cortés (6 shared papers)
- Journals
- Annals of Oncology (9 papers)The Breast (5 papers)Journal of Clinical Oncology (5 papers)npj Breast Cancer (4 papers)Clinical Breast Cancer (3 papers)
- Partner nations
- BrazilUnited StatesItaly
In The Last Decade
Laura Testa
60 papers receiving 2.2k citations
Laura Testa's Hit Papers
Peers
Comparison fields: 5 of 88
- Cancer Research 754
- Oncology 646
- Pulmonary and Respiratory Medicine 526
- Infectious Diseases 140
- Cardiology and Cardiovascular Medicine 99
Countries citing papers authored by Laura Testa
This map shows the geographic impact of Laura Testa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Testa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Testa more than expected).
Fields of papers citing papers by Laura Testa
This network shows the impact of papers produced by Laura Testa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Testa. The network helps show where Laura Testa may publish in the future.
Co-authors
The 25 scholars most cited alongside Laura Testa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 75 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial Hit paper breakdown → | 2022 | 404 |
| 2 | Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 387 |
| 3 | Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study Hit paper breakdown → | 2021 | 275 |
| 4 | Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes Hit paper breakdown → | 2024 | 150 |
| 5 | Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01 Hit paper breakdown → | 2024 | 113 |
| 6 | 2019 | 108 | |
| 7 | 2003 | 106 | |
| 8 | 2019 | 99 | |
| 9 | 2020 | 48 | |
| 10 | 2022 | 36 | |
| 11 | 2013 | 35 | |
| 12 | 2022 | 35 | |
| 13 | 2024 | 35 | |
| 14 | 2018 | 33 | |
| 15 | 2021 | 33 | |
| 16 | 1996 | 27 | |
| 17 | 2024 | 23 | |
| 18 | 1997 | 21 | |
| 19 | 2013 | 21 | |
| 20 | 2022 | 20 |
About Laura Testa
Laura Testa is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Complementary and alternative medicine, having authored 75 papers that have together received 2.2k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (25 papers), Advanced Breast Cancer Therapies (14 papers), Cancer Immunotherapy and Biomarkers (10 papers), Chemotherapy-induced cardiotoxicity and mitigation (7 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers), Cancer Treatment and Pharmacology (4 papers), HER2/EGFR in Cancer Research (4 papers) and Cardiovascular and exercise physiology (3 papers). The work is most often cited by research in Cancer Research (754 citations), Oncology (646 citations), Pulmonary and Respiratory Medicine (526 citations), Infectious Diseases (140 citations) and Cardiology and Cardiovascular Medicine (99 citations). Laura Testa has collaborated with scholars based in Brazil, United States and Italy. Frequent co-authors include Nadia Harbeck, Seock‐Ah Im, Rebecca Alexandra Dent, Eric P. Winer, Vassiliki Karantza, Peter E. Schmid, Stefania Zambelli, Javier Cortés, Anthony Gonçalvès and Fabrice André. Their work appears in journals such as Annals of Oncology, The Breast, Journal of Clinical Oncology, npj Breast Cancer and Clinical Breast Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.